Literature DB >> 28248909

Maintenance therapy with salicylates is associated with aortic stiffening in patients with inflammatory bowel disease.

Luca Zanoli1, Pierre Boutouyrie, Paolo Lentini, Stefania Rastelli, Pietro Castellino.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28248909     DOI： 10.1097/HJH.0000000000001235

Source DB:  PubMed          Journal:  J Hypertens        ISSN： 0263-6352            Impact factor:   4.844


× No keyword cloud information.
  4 in total

1.  The effect of tumor necrosis factor antagonists on functional aortic stiffening.

Authors:  Luca Zanoli; Antonio Granata; Paolo Lentini; Pietro Castellino; Pasquale Fatuzzo
Journal:  Clin Rheumatol       Date:  2017-06-03       Impact factor: 2.980

Review 2.  Arterial Stiffness in the Heart Disease of CKD.

Authors:  Luca Zanoli; Paolo Lentini; Marie Briet; Pietro Castellino; Andrew A House; Gerard M London; Lorenzo Malatino; Peter A McCullough; Dimitri P Mikhailidis; Pierre Boutouyrie
Journal:  J Am Soc Nephrol       Date:  2019-04-30       Impact factor: 10.121

3.  Inflammation and Aortic Pulse Wave Velocity: A Multicenter Longitudinal Study in Patients With Inflammatory Bowel Disease.

Authors:  Luca Zanoli; Kadir Ozturk; Maria Cappello; Gaetano Inserra; Giulio Geraci; Antonio Tuttolomondo; Daniele Torres; Antonio Pinto; Andrea Duminuco; Gaia Riguccio; Musa B Aykan; Giuseppe Mulé; Santina Cottone; Alessandra F Perna; Stephane Laurent; Pasquale Fatuzzo; Pietro Castellino; Pierre Boutouyrie
Journal:  J Am Heart Assoc       Date:  2019-02-05       Impact factor: 5.501

Review 4.  Vascular consequences of inflammation: a position statement from the ESH Working Group on Vascular Structure and Function and the ARTERY Society.

Authors:  Luca Zanoli; Marie Briet; Jean P Empana; Pedro G Cunha; Kaisa M Mäki-Petäjä; Athanase D Protogerou; Alain Tedgui; Rhian M Touyz; Ernesto L Schiffrin; Bart Spronck; Philippe Bouchard; Charalambos Vlachopoulos; Rosa M Bruno; Pierre Boutouyrie
Journal:  J Hypertens       Date:  2020-09       Impact factor: 4.776
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.